Altimmune (ALT) stock dips as higher-than-expected R&D costs lead to a Q4 2025 earnings miss for the company. Read more here.

Altimmune Inc (ALT) strengthens its financial position with a $75 million capital raise and prepares for pivotal Phase 3 trials amidst competitive MASH market challenges.

A liver enzyme known as ALT plays an important role in breaking down proteins in the digestive process. High levels of ALT in the blood can indicate liver issues. Implementing these strategies may ...

Sign up for the daily CJR newsletter. When Hillary Clinton in a speech last week uttered the phrase “alt-right,” devotees flocked to the internet to celebrate the ...